Reduced glutathione and Parkinson's disease

Movement Disorders

Volumn 25, Issue 15, 2010, Pages 2690-2691

  Sechi, Gian Pietro ^a  

^a UNIVERSITY OF SASSARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE TRANSPORTER; GLUTAMATE CYSTEINE LIGASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 4;

BLOOD BRAIN BARRIER; CLINICAL TRIAL; DOPAMINERGIC NERVE CELL; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG INFUSION; DRUG MEGADOSE; DRUG METABOLISM; HUMAN; LETTER; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STRIATONIGRAL DEGENERATION; TREATMENT INDICATION;

ANTIPARKINSON AGENTS; GLUTATHIONE; HUMANS; PARKINSON DISEASE;

EID: 78349269078     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.23383     Document Type: Letter

References (5)

1. Hauser RA, Lyons KE, McClain T, Carter S, Perlmutter D. Randomized, double-blind, pilot evaluation of intravenous glutathione in Parkinson's disease. Mov Disord 2009; 24: 979-983.
2. Okun MS, Lang A, Jankovic J. Based on the available randomized trial patients should say no to glutathione for Parkinson's disease. Mov Disord 2010; 25: 961-962.
3. More SM, Vince R. Design, synthesis and biological evaluation of glutathione peptidomimetics as components of anti-parkinson prodrugs. J Med Chem 2008; 51: 4581-4588.
4. Sechi G, Deledda MG, Bua G, et al. Reduced intravenous glutathione in the treatment of early Parkinson's disease. Prog Neuropsychopharmacol Biol Psychiatry 1996; 20: 1159-1170.
5. Sechi G, Nuvoli S, Agnetti V, et al. Influence of parenteral GSH on striatal dopamine transporter in PD. Mov Disord 2006; 21(Suppl. 15): S579.